Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Share-based Compensation of $6.3 million for Q1 2026, up 7.01% year-on-year from $5.8 million in Q1 2025, and up 10.58% on a QoQ basis from $5.7 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Share-based Compensation data on file, last reported at $6.3 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 7.01% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.2 million (up 26.87% YoY), and the FY2025 full-year result was $24.8 million, up 11.36% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.3 million, up from $5.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.2 million in Q1 2024 and bottomed at $1.9 million in Q1 2022.
- The 5-year median for Share-based Compensation is $4.4 million (2024), against an average of $4.4 million.
- The widest annual swing landed in 2024, when Share-based Compensation jumped 185.2%; it then fell 29.07% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2022, then soared by 120.66% to $4.2 million in 2023, then rose by 21.67% to $5.2 million in 2024, then increased by 9.48% to $5.7 million in 2025, then advanced by 10.58% to $6.3 million in 2026.
- The last three Share-based Compensation figures came in at $6.3 million (Q1 2026), $5.7 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Dec 31, 2025 | 5.66 Mn |
| Sep 30, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.67 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |
| Sep 30, 2023 | 3.81 Mn |
| Sep 30, 2023 | 3.81 Mn |
| Jun 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.30 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 1.52 Mn |
| Jun 30, 2021 | 1.52 Mn |
| Mar 31, 2021 | 1.57 Mn |
| Mar 31, 2021 | 1.57 Mn |
| Dec 31, 2020 | 1.47 Mn |
| Dec 31, 2020 | 1.47 Mn |
| Sep 30, 2020 | 1.48 Mn |
| Sep 30, 2020 | 1.48 Mn |
| Jun 30, 2020 | 1.79 Mn |
| Jun 30, 2020 | 1.79 Mn |
| Mar 31, 2020 | 1.52 Mn |
| Mar 31, 2020 | 1.52 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Sep 30, 2019 | 817,060.00 |
| Sep 30, 2019 | 817,060.00 |
| Jun 30, 2019 | 924,996.00 |
| Jun 30, 2019 | 924,996.00 |
| Mar 31, 2019 | 933,411.00 |
| Mar 31, 2019 | 933,411.00 |
| Dec 31, 2018 | 1.03 Mn |
| Dec 31, 2018 | 1.03 Mn |
| Sep 30, 2018 | 758,176.00 |
| Sep 30, 2018 | 758,176.00 |
| Jun 30, 2018 | 791,507.00 |
| Jun 30, 2018 | 791,507.00 |
| Mar 31, 2018 | 971,340.00 |
| Mar 31, 2018 | 971,340.00 |
| Dec 31, 2017 | 485,510.00 |
| Dec 31, 2017 | 485,510.00 |
| Sep 30, 2017 | 529,738.00 |
| Sep 30, 2017 | 529,738.00 |
| Jun 30, 2017 | 638,569.00 |
| Jun 30, 2017 | 638,569.00 |
| Mar 31, 2017 | 754,144.00 |
| Mar 31, 2017 | 754,144.00 |
| Dec 31, 2016 | 488,645.00 |
| Dec 31, 2016 | 488,645.00 |
| Sep 30, 2016 | 532,202.00 |
| Sep 30, 2016 | 532,202.00 |
| Jun 30, 2016 | 357,269.00 |
| Jun 30, 2016 | 357,269.00 |
| Mar 31, 2016 | 457,969.00 |
| Mar 31, 2016 | 457,969.00 |
| Dec 31, 2015 | 576,342.00 |
| Dec 31, 2015 | 576,342.00 |
| Sep 30, 2015 | 330,770.00 |
| Sep 30, 2015 | 330,770.00 |
| Jun 30, 2015 | 363,895.00 |
| Jun 30, 2015 | 363,895.00 |
| Mar 31, 2015 | 314,451.00 |
| Mar 31, 2015 | 314,451.00 |
| Dec 31, 2014 | 287,643.00 |
| Dec 31, 2014 | 287,643.00 |
| Sep 30, 2014 | 444,626.00 |
| Sep 30, 2014 | 444,626.00 |
| Jun 30, 2014 | 22,570.00 |
| Jun 30, 2014 | 22,570.00 |
| Mar 31, 2014 | 23,130.00 |
| Mar 31, 2014 | 23,130.00 |
| Dec 31, 2013 | 42,550.00 |
| Dec 31, 2013 | 42,550.00 |
| Sep 30, 2013 | 46,665.00 |
| Sep 30, 2013 | 46,665.00 |
| Jun 30, 2013 | 44,888.00 |
| Jun 30, 2013 | 44,888.00 |
| Mar 31, 2013 | 41,752.00 |
| Mar 31, 2013 | 41,752.00 |
| Dec 31, 2012 | 204,274.00 |
| Dec 31, 2012 | 204,274.00 |
| Sep 30, 2012 | 45,585.00 |
| Sep 30, 2012 | 45,585.00 |
| Jun 30, 2012 | 45,090.00 |
| Jun 30, 2012 | 45,090.00 |
| Mar 31, 2012 | 45,090.00 |
| Mar 31, 2012 | 45,090.00 |
| Dec 31, 2011 | 248,923.00 |
| Dec 31, 2011 | 248,923.00 |
| Sep 30, 2011 | 48,985.00 |
| Sep 30, 2011 | 48,985.00 |
| Jun 30, 2011 | 65,076.00 |
| Jun 30, 2011 | 65,076.00 |
| Mar 31, 2011 | 53,751.00 |
| Mar 31, 2011 | 53,751.00 |
| Dec 31, 2010 | 245,982.00 |
| Dec 31, 2010 | 245,982.00 |
| Sep 30, 2010 | 35,972.00 |
| Sep 30, 2010 | 35,972.00 |